Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,883 shares of the medical research company’s stock after acquiring an additional 824 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,061,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Value Partners Investments Inc. lifted its holdings in Thermo Fisher Scientific by 9.0% in the 3rd quarter. Value Partners Investments Inc. now owns 2,580 shares of the medical research company’s stock valued at $1,312,000 after purchasing an additional 214 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Thermo Fisher Scientific by 7.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 89,047 shares of the medical research company’s stock worth $45,056,000 after acquiring an additional 6,419 shares during the period. NBT Bank N A NY lifted its holdings in shares of Thermo Fisher Scientific by 1,062.6% during the 3rd quarter. NBT Bank N A NY now owns 11,870 shares of the medical research company’s stock worth $6,008,000 after acquiring an additional 10,849 shares during the period. River Street Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 17.0% during the 3rd quarter. River Street Advisors LLC now owns 564 shares of the medical research company’s stock worth $285,000 after acquiring an additional 82 shares during the period. Finally, Chicago Partners Investment Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 11.2% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 604 shares of the medical research company’s stock worth $279,000 after acquiring an additional 61 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.1 %

NYSE:TMO traded down $0.68 during trading hours on Tuesday, hitting $572.87. The stock had a trading volume of 1,771,703 shares, compared to its average volume of 1,548,671. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The business has a 50 day simple moving average of $575.72 and a two-hundred day simple moving average of $535.12. The company has a market cap of $218.67 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Analysts predict that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TMO. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Raymond James increased their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Evercore ISI increased their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, The Goldman Sachs Group increased their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,277 shares of company stock valued at $35,373,364. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.